Healthcare / Diagnostics & ResearchKOSDAQ
$2725.00
-245.00 (-8.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-31.0B · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$95.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.7%
↓Gross Margin
-78.2%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-68.8%
FCF CAGR
—
FCF margin
-99.1%
FCF / Net income
0.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $31.26B · net income $-82.12B · FCF $-30.97B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $31.26B | $31.26B | $112.46B | $348.64B | $1033.86B |
| Net Income | $-82.12B | $-82.12B | $-347.6M | $-3.17B | $346.67B |
| EBITDA | $-85.90B | $-85.90B | $23.40B | $13.79B | $480.76B |
| EPS | -2332.00 | -2332.00 | -14.00 | -91.00 | 9212.00 |
| Gross Margin | -78.2% | -78.2% | 47.7% | 48.8% | 79.3% |
| Operating Margin | -202.5% | -202.5% | -3.7% | 6.3% | 45.4% |
| Net Margin | -262.7% | -262.7% | -0.3% | -0.9% | 33.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.10 | 0.13 | 0.12 |
| Current Ratio | 16.86 | 16.86 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-30.97B | $-30.97B | $17.85B | $-122.56B | $350.29B |
| Returns | |||||
| ROE | -14.7% | -14.7% | -0.1% | -0.5% | 56.1% |
| Valuation | |||||
| P/E | — | — | — | — | 1.35 |
| EV/EBITDA | — | — | -3.52 | 7.80 | 0.15 |
| P/B | 0.17 | 0.17 | 0.30 | 0.53 | 0.76 |
| Growth & Yield | |||||
| Revenue Growth | -72.2% | -72.2% | -67.7% | -66.3% | — |
| EPS Growth | -16557.1% | -16557.1% | 84.6% | -101.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-14.00 → -2332.00
Residual
-47.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.